# Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

> **NCT02616055** · PHASE2 · TERMINATED · sponsor: **Kadmon Corporation, LLC** · enrollment: 15 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease (ADPKD)

## Interventions

- **DRUG:** tesevatinib

## Key facts

- **NCT ID:** NCT02616055
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-25
- **Primary completion:** 2016-12-21
- **Final completion:** 2016-12-21
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor opened Phase 2 Study.
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616055, "Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02616055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*